Steven Cohen Nektar Therapeutics Transaction History

Point72 Asset Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.51 - $1.05 $763,836 - $1.57 Million	1,497,719 Added 6551.99%	1,520,578 $912,000
Q2 2023 Aug 14, 2023	BUY	$0.53 - $1.03 $12,115 - $23,544	22,859 New	22,859 $13,000
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $1.41 Million - $2.74 Million	-443,800 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.16 - $13.72 $76,960 - $253,820	-18,500 Reduced 4.0%	443,800 $2.39 Million
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $701,784 - $1.19 Million	-64,800 Reduced 12.29%	462,300 $6.25 Million
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $6.89 Million - $9.93 Million	527,100 New	527,100 $9.47 Million
Q2 2020 Aug 14, 2020	SELL	$16.86 - $23.44 $264,331 - $367,492	-15,678 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$14.47 - $27.96 $226,860 - $438,356	15,678 New	15,678 $280,000
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $1.02 Million - $2.31 Million	-22,100 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $1.27 Million - $2.4 Million	22,100 New	22,100 $2.35 Million

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.